JP2022513299A5 - - Google Patents
Info
- Publication number
- JP2022513299A5 JP2022513299A5 JP2021534939A JP2021534939A JP2022513299A5 JP 2022513299 A5 JP2022513299 A5 JP 2022513299A5 JP 2021534939 A JP2021534939 A JP 2021534939A JP 2021534939 A JP2021534939 A JP 2021534939A JP 2022513299 A5 JP2022513299 A5 JP 2022513299A5
- Authority
- JP
- Japan
- Prior art keywords
- bifunctional molecule
- molecule according
- bifunctional
- m6pr
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024212140A JP2025041675A (ja) | 2018-12-19 | 2024-12-05 | リソソーム標的化のための二官能性分子ならびに関連する組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862782193P | 2018-12-19 | 2018-12-19 | |
| US62/782,193 | 2018-12-19 | ||
| US201962932347P | 2019-11-07 | 2019-11-07 | |
| US62/932,347 | 2019-11-07 | ||
| PCT/US2019/067228 WO2020132100A1 (en) | 2018-12-19 | 2019-12-18 | Bifunctional molecules for lysosomal targeting and related compositions and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024212140A Division JP2025041675A (ja) | 2018-12-19 | 2024-12-05 | リソソーム標的化のための二官能性分子ならびに関連する組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022513299A JP2022513299A (ja) | 2022-02-07 |
| JP2022513299A5 true JP2022513299A5 (enExample) | 2022-12-26 |
| JP7674740B2 JP7674740B2 (ja) | 2025-05-12 |
Family
ID=71102305
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021534939A Active JP7674740B2 (ja) | 2018-12-19 | 2019-12-18 | リソソーム標的化のための二官能性分子ならびに関連する組成物および方法 |
| JP2024212140A Pending JP2025041675A (ja) | 2018-12-19 | 2024-12-05 | リソソーム標的化のための二官能性分子ならびに関連する組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024212140A Pending JP2025041675A (ja) | 2018-12-19 | 2024-12-05 | リソソーム標的化のための二官能性分子ならびに関連する組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20220023434A1 (enExample) |
| EP (1) | EP3897747A4 (enExample) |
| JP (2) | JP7674740B2 (enExample) |
| KR (1) | KR20210104828A (enExample) |
| CN (1) | CN113301925A (enExample) |
| AU (1) | AU2019404061A1 (enExample) |
| BR (1) | BR112021012113A2 (enExample) |
| CA (1) | CA3123086A1 (enExample) |
| IL (1) | IL283958A (enExample) |
| MX (1) | MX2021007376A (enExample) |
| SG (1) | SG11202106209RA (enExample) |
| WO (1) | WO2020132100A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230097887A1 (en) | 2018-04-09 | 2023-03-30 | Yale University | Bi-functional Molecules to Degrade Circulating Proteins |
| US12485178B2 (en) | 2018-04-09 | 2025-12-02 | Yale University | Bifunctional small molecules to target the selective degradation of circulating proteins |
| EP3773727A4 (en) | 2018-04-09 | 2022-05-04 | Yale University | BIFUNCTIONAL SMALL MOLECULES TO TARGETING THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS |
| AU2019404061A1 (en) | 2018-12-19 | 2021-07-22 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional molecules for lysosomal targeting and related compositions and methods |
| KR20220099963A (ko) * | 2019-10-10 | 2022-07-14 | 예일 유니버시티 | 세포 수용체를 통한 분자 분해제로서의 조작된 항체 |
| EP4041262A4 (en) * | 2019-10-10 | 2024-03-13 | Yale University | Targeted bifunctional degraders |
| CN115379850A (zh) | 2019-12-24 | 2022-11-22 | 裘美娜治疗公司 | 再生性多肽及其用途 |
| WO2021155317A1 (en) | 2020-01-31 | 2021-08-05 | Avilar Therapeutics, Inc. | Asgpr-binding compounds for the degradation of extracellular proteins |
| KR20220148235A (ko) | 2020-02-28 | 2022-11-04 | 젠자임 코포레이션 | 최적화된 약물 접합을 위한 변형된 결합 폴리펩티드 |
| EP4172188A4 (en) * | 2020-06-30 | 2025-02-19 | The Board of Trustees of the Leland Stanford Junior University | Cis-binding siglec agonists and related compositions and methods |
| WO2022035997A1 (en) * | 2020-08-11 | 2022-02-17 | Avilar Therapeutics, Inc. | In vivo assembly of asgpr binding therapeutics |
| CN114438088B (zh) * | 2020-11-03 | 2025-05-23 | 韩达 | 一种溶酶体靶向的核酸嵌合体的制备及应用 |
| EP4281115A1 (en) * | 2021-01-19 | 2023-11-29 | Novartis AG | Degradation of extracellular targets |
| WO2022194078A1 (zh) * | 2021-03-15 | 2022-09-22 | 北京大学 | 用于靶分子修饰的缀合物及其制备方法 |
| WO2022212918A1 (en) * | 2021-04-02 | 2022-10-06 | The Board Of Trustees Of The Leland Stanford Junior University | Bispecific molecules and related compositions and methods |
| KR20240017423A (ko) | 2021-05-03 | 2024-02-07 | 아빌라 테라퓨틱스, 인크. | 이뮤노글로불린 및 다른 단백질의 분해를 위한 강력한 asgpr-결합 화합물 |
| WO2022271466A1 (en) | 2021-06-21 | 2022-12-29 | Juvena Therapeutics, Inc. | Regenerative polypeptides and uses thereof |
| WO2022271981A2 (en) * | 2021-06-23 | 2022-12-29 | Lycia Therapeutics, Inc. | Bifunctional compounds containing igf-2 polypeptides |
| AU2022310346A1 (en) | 2021-07-14 | 2024-01-25 | Lycia Therapeutics, Inc. | M6pr cell surface receptor binding compounds and conjugates |
| EP4370157A1 (en) | 2021-07-14 | 2024-05-22 | Lycia Therapeutics, Inc. | Asgpr cell surface receptor binding compounds and conjugates |
| EP4377352A2 (en) | 2021-07-30 | 2024-06-05 | Vib Vzw | Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation |
| CN115975039A (zh) * | 2021-10-15 | 2023-04-18 | 中山大学 | 重组融合抗体和抗体-药物偶联物及其用途 |
| CN114522244B (zh) * | 2022-01-28 | 2023-09-01 | 浙江大学医学院附属第四医院 | 视黄酸修饰的lytac分子及其制备方法和应用 |
| US12569567B2 (en) * | 2022-01-28 | 2026-03-10 | The Fourth Affiliated Hospital Of Zhejiang University School Of Medicine | Retinoic acid modified lysosome targeting chimera molecule, preparation method and applications thereof |
| FR3132634B1 (fr) * | 2022-02-15 | 2025-04-25 | Nanomedsyn | Composés bifonctionnels ciblant le récepteur du mannose 6-phosphate cation-indépendant |
| IL315579A (en) * | 2022-03-15 | 2024-11-01 | Univ Yale | Small bifunctional compounds to target selective degradation of circulating proteins |
| KR20250004953A (ko) * | 2022-03-15 | 2025-01-08 | 예일 유니버시티 | 순환하는 단백질을 분해하기 위한 이-작용성 분자 |
| EP4496591A2 (en) * | 2022-03-22 | 2025-01-29 | Wisconsin Alumni Research Foundation | Transferrin-based lysosome targeting degraders |
| KR20250028349A (ko) * | 2022-06-23 | 2025-02-28 | 드라우프니르 바이오 에이피에스 | 리소좀 내 세포외 표적의 분해를 선택적으로 유도하는 이작용성 분자 |
| WO2024003300A1 (en) * | 2022-06-30 | 2024-01-04 | Aptadegrad, S.L. | Dna aptamer conjugates recognizing and degrading coronavirus proteins |
| GB202211100D0 (en) * | 2022-07-29 | 2022-09-14 | Stam Jord Cornelis | Lysosomal degradation |
| GB202212077D0 (en) | 2022-08-18 | 2022-10-05 | Tribune Therapeutics Ab | Agents that inhibit ccn ligand-induced signalling for treating disease |
| WO2024068753A1 (en) * | 2022-09-28 | 2024-04-04 | Glycoera Ag | Glycan-mediated protein degradation |
| WO2024089609A1 (en) | 2022-10-25 | 2024-05-02 | Ablynx N.V. | Glycoengineered fc variant polypeptides with enhanced effector function |
| AU2023367846A1 (en) * | 2022-10-26 | 2025-05-01 | Amgen Inc. | Multispecific molecules for clearance of immunoglobulins in the treatment of autoantibody-induced diseases |
| CN120835794A (zh) | 2023-01-18 | 2025-10-24 | 利西亚治疗公司 | M6pr结合化合物和缀合物 |
| WO2024182772A2 (en) * | 2023-03-02 | 2024-09-06 | Avilar Therapeutics, Inc. | Mannose 6-phosphate receptor binding compounds for the degradation of extracellular proteins |
| CN118697896A (zh) * | 2023-03-27 | 2024-09-27 | 中山大学 | 嵌合体在靶向蛋白质降解技术中的应用 |
| PL445164A1 (pl) * | 2023-06-07 | 2024-12-09 | Recepton Spółka Z Ograniczoną Odpowiedzialnością | Cząsteczki indukujące internalizację receptorów i białek zewnątrzkomórkowych |
| WO2025133234A1 (en) * | 2023-12-22 | 2025-06-26 | Draupnir Bio Aps | Sortilin binders and bifunctional compounds thereof |
| WO2025147169A1 (en) * | 2024-01-05 | 2025-07-10 | Green Cross Corporation | Multispecific antibody for lysosomal degradation |
| WO2025189160A1 (en) * | 2024-03-08 | 2025-09-12 | The Board Of Trustees Of The Leland Stanford Junior University | Trogocytosis-inducing bispecific molecules and methods of use |
| WO2025238106A1 (en) | 2024-05-15 | 2025-11-20 | M6P Therapeutics (Switzerland) GmbH | Lysosome-targeting degradation fusion design |
| WO2026017888A1 (en) * | 2024-07-18 | 2026-01-22 | Universiteit Gent | Targeted protein degradation and recruitment |
| WO2026019282A1 (ko) * | 2024-07-18 | 2026-01-22 | 한국생명공학연구원 | 라이소좀 타겟팅 키메라, 이의 제조 방법 및 이를 포함하는 약학 조성물 |
| CN119345384A (zh) * | 2024-11-01 | 2025-01-24 | 珠海市睿森生物科技有限公司 | 一种多肽药物嵌合体及其制备方法 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2752892A (en) | 1991-09-26 | 1993-04-27 | Oklahoma Medical Research Foundation | Fusion proteins targeted to lysosomes, for the treatment of aids |
| DK129293D0 (da) | 1993-11-16 | 1993-11-16 | Carlsberg Lab | Carbonhydratholdige forbindelser, der kan binde sig til carbonhydratbindende receptorer |
| US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US6083725A (en) | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
| AU2662999A (en) * | 1998-02-09 | 1999-08-23 | Genzyme Corporation | Nucleic acid delivery vehicles |
| US6093382A (en) | 1998-05-16 | 2000-07-25 | Bracco Research Usa Inc. | Metal complexes derivatized with folate for use in diagnostic and therapeutic applications |
| AU770340B2 (en) | 1998-10-08 | 2004-02-19 | Biorion Technologies B.V. | Peptide-based carrier devices for stellate cells |
| US6426208B1 (en) | 1999-11-12 | 2002-07-30 | Harbor-Ucla Research And Education Institute | Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof |
| US20040009907A1 (en) | 2001-02-26 | 2004-01-15 | Alsobrook John P. | Proteins and nucleic acids encoding same |
| EP1284752A4 (en) * | 2000-04-26 | 2004-08-18 | Elusys Therapeutics Inc | BISPECIFIC MOLECULES AND USES THEREOF |
| NZ524980A (en) | 2000-09-01 | 2005-10-28 | Biogen Idec Inc | Novel CD40:CD154 binding interruptor compounds and use thereof to treat immunological complications |
| EP1385538B1 (en) | 2001-04-05 | 2013-01-30 | The Johns Hopkins University | Chimeric Vaccines comprising the lumenal domain of LAMP-1 or LAMP-2 |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US20030049203A1 (en) | 2001-08-31 | 2003-03-13 | Elmaleh David R. | Targeted nucleic acid constructs and uses related thereto |
| US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
| ES2411007T3 (es) * | 2001-10-10 | 2013-07-04 | Novo Nordisk A/S | Remodelación y glicoconjugación de péptidos |
| US20050191309A1 (en) | 2002-05-06 | 2005-09-01 | Kakkis Emil D. | Induction of antigen specific immunologic tolerance |
| US7485314B2 (en) | 2002-05-06 | 2009-02-03 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Induction of antigen specific immunologic tolerance |
| AU2002950217A0 (en) | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
| ES2330004T3 (es) | 2003-05-20 | 2009-12-03 | Pharmaxis Pty Ltd. | Compuestos de manosa-6-fosfonato para el tratamiento de enfermedades inflamatorias. |
| US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| US8889127B2 (en) | 2004-07-01 | 2014-11-18 | Icahn School Of Medicine At Mount Sinai | Targeted protein replacement for the treatment of lysosomal storage disorders |
| GB0423405D0 (en) | 2004-10-21 | 2004-11-24 | Novartis Ag | Organic compounds |
| EP1745802A1 (en) | 2005-07-20 | 2007-01-24 | Kreatech Biotechnology B.V. | Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes |
| US20070104648A1 (en) | 2005-11-09 | 2007-05-10 | Glyconix Corporation | Compositions, methods of preparing amino acids, and nuclear magnetic resonance spectroscopy |
| AU2007234698B2 (en) | 2006-04-07 | 2013-08-01 | The Board Of Regents Of The University Of Texas System | Methods and compositions related to adenoassociated virus-phage particles |
| US20080057072A1 (en) | 2006-08-31 | 2008-03-06 | Alcon Manufacturing, Ltd. | Antagonists of ci-m6p/igf2r for prevention and treatment of ctgf-mediated ocular disorders |
| RU2500685C2 (ru) | 2006-11-10 | 2013-12-10 | Кара Терапеутикс, Инк | Синтетические пептидные амиды |
| WO2008089339A2 (en) | 2007-01-18 | 2008-07-24 | Genzyme Corporation | Oligosaccharide conjugates for cellular targeting |
| ES3029483T3 (en) | 2008-09-17 | 2025-06-24 | Endocyte Inc | Folate receptor binding conjugates of antifolates |
| CN102369023A (zh) * | 2008-12-16 | 2012-03-07 | 建新公司 | 寡糖-蛋白缀合物 |
| US8557783B2 (en) | 2009-04-28 | 2013-10-15 | Pharmaxis Pty Limited | Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders |
| US8962573B2 (en) | 2009-07-03 | 2015-02-24 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Compounds targeting the cation-independent mannose 6-phosphate receptor |
| EP2480235A4 (en) | 2009-09-24 | 2013-05-08 | Univ Louisville Res Found | NEW IODO-PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ILLNESSES AND SUFFERING IN CONNECTION WITH THE MACROPHAGE MIGRATION-INHIBITING FACTOR |
| FR2952372B1 (fr) | 2009-11-10 | 2012-03-23 | Centre Nat Rech Scient | Nouveaux derives de mannopyranoside ayant une activite anticancereuse |
| EP2343081A1 (en) | 2009-12-31 | 2011-07-13 | Rijksuniversiteit Groningen | Interferon analogs |
| US20120121592A1 (en) * | 2010-10-13 | 2012-05-17 | Baylor Research Institute | Targeting Antigens to Human Dendritic Cells Via DC-Asialoglycoprotein Receptor to Produce IL-10 Regulatory T-Cells |
| HRP20180291T1 (hr) | 2011-05-27 | 2018-03-23 | Amicus Therapeutics, Inc. | Postupci za sparivanje ciljajućeg peptida na rekombinantne lizosomalne enzime za poboljšano liječenje lizosomskih bolesti nakupljanja |
| EP2825553B1 (en) * | 2012-03-14 | 2018-07-25 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
| CA3140358A1 (en) | 2012-07-31 | 2014-02-06 | Bioasis Technologies, Inc. | Dephosphorylated lysosomal storage disease proteins and methods of use thereof |
| WO2014082080A2 (en) | 2012-11-26 | 2014-05-30 | Callidus Biopharma, Inc. | Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases |
| WO2014089209A2 (en) | 2012-12-04 | 2014-06-12 | Abbvie, Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins |
| AU2014218854B2 (en) | 2013-02-20 | 2019-01-24 | Valerion Therapeutics, Llc | Methods and compositions for treatment of Pompe disease |
| ES2824026T3 (es) | 2013-05-03 | 2021-05-11 | Univ Yale | Compuestos miméticos de anticuerpos sintéticos (SyAM) dirigidos al cáncer, especialmente cáncer de próstata |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
| WO2015143091A1 (en) * | 2014-03-19 | 2015-09-24 | Genzyme Corporation | Site-specific glycoengineering of targeting moieties |
| PL3145934T3 (pl) | 2014-05-19 | 2021-08-16 | Pfizer Inc. | Podstawione związki 6,8-dioksabicyklo[3.2.1]oktano-2,3-diolu jako środki kierujące do ASGPR |
| WO2015191934A2 (en) | 2014-06-11 | 2015-12-17 | Abbvie Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases |
| EP3185889B1 (en) * | 2014-08-11 | 2020-07-15 | Shire Human Genetic Therapies, Inc. | Mannose-6-phosphate bearing peptides fused to lysosomal enzymes |
| US20170290806A1 (en) | 2014-09-08 | 2017-10-12 | Temple University-Of The Commonwealth System Of Higher Education | PCSK9 Inhibitors and Methods of Use Thereof |
| CA3205824A1 (en) | 2014-10-09 | 2016-04-14 | Genzyme Corporation | Glycoengineered antibody drug conjugates |
| US20160166679A1 (en) | 2014-12-12 | 2016-06-16 | Purdue Research Foundation | Method of treatment using folate conjugates and tyrosine kinase inhibitors |
| IL296285A (en) | 2015-07-06 | 2022-11-01 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| FR3041345B1 (fr) | 2015-09-18 | 2019-06-14 | Nanomedsyn | Composes polysaccharides multi-fonctionnalises et leur utilisation pour cibler le recepteur du mannose 6-phosphate cation-independant |
| EP3356415B1 (en) * | 2015-09-29 | 2024-05-01 | Amgen Inc. | Asgr inhibitors for reduzing cholesterol levels |
| DK3386534T3 (da) | 2015-12-08 | 2020-11-30 | Regeneron Pharma | Sammensætninger og fremgangsmåder til internalisering af enzymer |
| KR20260018979A (ko) * | 2016-02-05 | 2026-02-09 | 젠맵 에이/에스 | 개선된 내재화 특징을 갖는 다중특이적 항원-결합 분자 |
| WO2017212019A1 (en) | 2016-06-09 | 2017-12-14 | Centre National De La Recherche Scientifique (Cnrs) | Raav with chemically modified capsid |
| DK3635009T3 (da) | 2017-06-07 | 2026-03-30 | Regeneron Pharma | Sammensætninger og fremgangsmåder til internalisering af enzymer |
| EP3773727A4 (en) | 2018-04-09 | 2022-05-04 | Yale University | BIFUNCTIONAL SMALL MOLECULES TO TARGETING THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS |
| WO2019199621A1 (en) | 2018-04-09 | 2019-10-17 | Yale University | Bi-functional molecules to degrade circulating proteins |
| AU2019404061A1 (en) | 2018-12-19 | 2021-07-22 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional molecules for lysosomal targeting and related compositions and methods |
| EP3997214B1 (en) | 2019-07-11 | 2023-08-02 | Centre National de la Recherche Scientifique | Chemically-modified adeno-associated virus |
| KR20220099963A (ko) | 2019-10-10 | 2022-07-14 | 예일 유니버시티 | 세포 수용체를 통한 분자 분해제로서의 조작된 항체 |
| EP4041262A4 (en) | 2019-10-10 | 2024-03-13 | Yale University | Targeted bifunctional degraders |
-
2019
- 2019-12-18 AU AU2019404061A patent/AU2019404061A1/en active Pending
- 2019-12-18 SG SG11202106209RA patent/SG11202106209RA/en unknown
- 2019-12-18 BR BR112021012113-7A patent/BR112021012113A2/pt unknown
- 2019-12-18 CN CN201980087886.9A patent/CN113301925A/zh active Pending
- 2019-12-18 EP EP19901042.2A patent/EP3897747A4/en active Pending
- 2019-12-18 CA CA3123086A patent/CA3123086A1/en active Pending
- 2019-12-18 US US17/311,779 patent/US20220023434A1/en not_active Abandoned
- 2019-12-18 WO PCT/US2019/067228 patent/WO2020132100A1/en not_active Ceased
- 2019-12-18 MX MX2021007376A patent/MX2021007376A/es unknown
- 2019-12-18 JP JP2021534939A patent/JP7674740B2/ja active Active
- 2019-12-18 KR KR1020217022461A patent/KR20210104828A/ko active Pending
-
2021
- 2021-06-14 IL IL283958A patent/IL283958A/en unknown
- 2021-10-12 US US17/499,272 patent/US11787865B2/en active Active
-
2023
- 2023-09-08 US US18/244,121 patent/US20230416377A1/en active Pending
-
2024
- 2024-12-05 JP JP2024212140A patent/JP2025041675A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022513299A5 (enExample) | ||
| JP7614094B2 (ja) | 薬物コンジュゲート | |
| Jones et al. | Blood–brain barrier transport of therapeutics via receptor-mediation | |
| US10174105B2 (en) | Use of VHH antibodies for the preparation of peptide vectors for delivering a substance of interest and their applications | |
| Adhikari et al. | Antibody‐Nanoparticle conjugates in therapy: combining the best of two worlds | |
| EP2976109B1 (en) | Cellular delivery of dna intercalating agents | |
| US12146238B2 (en) | Target-specific extracellular vesicles | |
| CN107847588A (zh) | 具有靶向部分及效应部分的分子构建体及其应用 | |
| JP2023515708A5 (enExample) | ||
| AU2020404817A1 (en) | Bispecific antibodies with alternatively matched interchain cysteines and uses thereof | |
| Nanaware-Kharade et al. | Therapeutic anti-methamphetamine antibody fragment-nanoparticle conjugates: synthesis and in vitro characterization | |
| JP2026065117A (ja) | 最適化された薬物コンジュゲーションのための改変された結合ポリペプチド | |
| KR20230043111A (ko) | Vhh를 포함하는 adc 또는 aoc, 및 사포닌 또는 리간드-사포닌 접합체를 포함하는 조합물 | |
| Khaleghi et al. | Camelid single-domain antibodies for targeting cancer nanotheranostics | |
| JP7652807B2 (ja) | 単一ドメイン抗体、サポニン及びエフェクター分子のコンジュゲート、それを含む医薬組成物、前記医薬組成物の治療的使用 | |
| Tian et al. | The use of peptide and protein vectors to cross the Blood-Brain barrier for the delivery of therapeutic concentration of biologics | |
| CA3219217A1 (en) | Antibody-protamine fusions as targeting compounds of a protamine-based nanoparticle | |
| CN120399079B (zh) | 靶向cd90的纳米抗体及其应用 | |
| CN120399078B (zh) | 靶向cd117的纳米抗体及其应用 | |
| EP4520768A1 (en) | Vhh-ch3 fusion proteins | |
| US11028132B1 (en) | Half-life optimized linker composition | |
| TW202535941A (zh) | 具有特製藥物對抗體比之抗體-藥物結合物 | |
| Ashique et al. | Nanobodies in Asthma Therapy: a Promising Frontier in Targeted Respiratory Treatment | |
| KR102215150B1 (ko) | 경구용 유전자 전달체 및 이의 용도 | |
| CN119751683A (zh) | 抗cd5纳米抗体及其在体内car细胞疗法中的应用 |